Savara Pharmaceuticals has announced the completion of a $20 million financing round to fund a pivotal Phase 3 clinical trial of its AeroVanc vancomycin DPI for the treatment of MRSA lung infections in cystic fibrosis patients. The company says that it expects enrollment for the study to begin by the end of the year.
In February 2015, Savara announced positive results from a Phase 2 study of AeroVanc for CF, which has received Fast Track, Orphan, and QIDP designation from the FDA.
Savara Pharmaceuticals CEO Rob Neville said, “The new financing will help support the AeroVanc Phase 3 trial, and expanding our pipeline with other new drugs for serious and life-shortening rare respiratory diseases. Research shows that people with CF have a more rapid decline in lung function when infected with MRSA, as well as a reduction in overall survival. Our efforts will hopefully result in the FDA approval of the first inhaled antibiotic for use in MRSA infected people with CF.”
Read the Savara press release.
